{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:39:01Z","timestamp":1794652741135,"version":"4.9.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>OnabotulinumtoxinA is an injectable medication that produces muscle relaxation through local chemical denervation at the neuromuscular junction. Discovery of onabotulinumtoxinA\u2019s aesthetic benefits occurred serendipitously in the 1980s at the intersection of several medical disciplines, including ophthalmology, neurology, otolaryngology, and dermatology. Patients receiving onabotulinumtoxinA for blepharospasm, hemifacial spasm, and dystonia noticed their periorbital wrinkles disappearing, particularly frown lines between the eyebrows called glabellar lines (GL).<\/jats:p>\n          <jats:p>Aesthetic use of onabotulinumtoxinA necessitated rigorous training programs and vigilant monitoring by Allergan. Approval for the GL indication was based on 2 similarly designed, double-blind, randomized, multicenter clinical studies. Subjects with moderate to severe GL receiving onabotulinumtoxinA achieved significantly greater improvement in GL severity than those receiving placebo. In subsequent studies, more than 80% of subjects were satisfied with onabotulinumtoxinA treatment through day 60, and many reported looking approximately 4 years younger at weeks 4 and 12 than at baseline. OnabotulinumtoxinA has a rapid onset of action, and peak effect occurs between 30 and 60 days. The median duration of response for dynamic GL in the initial studies was 120 days and response progressively improved with subsequent treatments. OnabotulinumtoxinA was well tolerated, and the 2 most common adverse events, headache and blepharoptosis, tended to decrease in frequency with repeat treatment.<\/jats:p>\n          <jats:p>The novel use of onabotulinumtoxinA for treating GL was an important step in addressing the clinical need for a noninvasive, straightforward, office-based procedure for facial lines that also left patients extremely satisfied with its treatment effects and represented the beginning of its widespread use for numerous aesthetic indications.<\/jats:p>","DOI":"10.1097\/md.0000000000032375","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:00:27Z","timestamp":1690484427000},"page":"e32375","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Jean","family":"Carruthers","sequence":"first","affiliation":[{"name":"University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Carruthers","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blitzer","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York, NY, USA"},{"name":"Mount Sinai West Hospital Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Eadie","sequence":"additional","affiliation":[{"name":"Former employee of Allergan plc, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan\/AbbVie, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240803","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1524-4725.2012.02582.x","article-title":"OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines.","volume":"38","author":"Glogau","year":"2012","journal-title":"Dermatol Surg"},{"key":"R2-20240803","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo- controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R3-20240803","first-page":"1","article-title":"Botulinum toxin type-A in the treatment of glabellar lines.","volume":"3","author":"Winter","year":"2009","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R4-20240803","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijom.2010.09.014","article-title":"The use of botulinum toxin type A in cosmetic facial procedures.","volume":"40","author":"Jaspers","year":"2011","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"suppl 4","key":"R5-20240803","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1524-4725.2010.01708.x","article-title":"OnabotulinumtoxinA treatment of mild glabellar lines in repose.","volume":"36","author":"Carruthers","year":"2010","journal-title":"Dermatol Surg"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/DSS.0000000000000424","article-title":"Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.","volume":"41","author":"Rivers","year":"2015","journal-title":"Dermatol Surg"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002341-200101000-00002","article-title":"Aesthetic surgery: diagnosing and healing the miscues of human facial expression.","volume":"17","author":"Khan","year":"2001","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042728-200305000-00003","article-title":"Social implications of hyperfunctional facial lines.","volume":"29","author":"Finn","year":"2003","journal-title":"Dermatol Surg"},{"key":"R10-20240803","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1176\/ajp.142.3.348","article-title":"Agitation-increased electromyogram activity in the corrugator muscle region: a possible explanation of the \u201cOmega sign\u201d?","volume":"142","author":"Greden","year":"1985","journal-title":"Am J Psychiatry"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/00006534-200003000-00046","article-title":"Temporal brow lift using botulinum toxin A.","volume":"105","author":"Ahn","year":"2000","journal-title":"Plast Reconstr Surg"},{"key":"R13-20240803","first-page":"778","article-title":"Complications associated with cutaneous aesthetic procedures.","volume":"13","author":"Hartmann","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"R14-20240803","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/archotol.1993.01880210108015","article-title":"Botulinum toxin for the treatment of hyperfunctional lines of the face.","volume":"119","author":"Blitzer","year":"1993","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1524-4725.1992.tb03295.x","article-title":"Treatment of glabellar frown lines with C. botulinum-A exotoxin.","volume":"18","author":"Carruthers","year":"1992","journal-title":"J Dermatol Surg Oncol"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00006534-199407000-00009","article-title":"Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study.","volume":"94","author":"Keen","year":"1994","journal-title":"Plast Reconstr Surg"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1524-4725.1996.tb00569.x","article-title":"Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study.","volume":"22","author":"Garcia","year":"1996","journal-title":"Dermatol Surg"},{"key":"R18-20240803","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archoto.123.4.389","article-title":"The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients.","volume":"123","author":"Blitzer","year":"1997","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R21-20240803","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.PRS.0000076504.79727.62","article-title":"Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.","volume":"112","author":"Carruthers","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"R22-20240803","first-page":"1","article-title":"One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines.","volume":"7","author":"Carruthers","year":"2004","journal-title":"J Clin Res"},{"key":"R23-20240803","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2009.06.040","article-title":"Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants.","volume":"61","author":"Brin","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R24-20240803","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/DSS.0000000000000704","article-title":"Repeated onabotulinumtoxinA treatment of glabellar lines at rest over three treatment cycles.","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol Surg"},{"key":"R25-20240803","first-page":"184","article-title":"Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids.","volume":"32","author":"Beer","year":"2006","journal-title":"Dermatol Surg"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications.","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.sap.0000244968.16977.1f","article-title":"An objective assessment of botulinum toxin A effect on superficial skin texture.","volume":"58","author":"Dessy","year":"2007","journal-title":"Ann Plast Surg"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1524-4725.2006.32325.x","article-title":"Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study.","volume":"33","author":"Fagien","year":"2007","journal-title":"Dermatol Surg"},{"issue":"suppl 3","key":"R31-20240803","first-page":"7","article-title":"Interventional neurology: treatment of neurological conditions with local injection of botulinum toxin.","volume":"54","author":"Brin","year":"1991","journal-title":"Arch Neurobiol (Madr)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:56:18Z","timestamp":1722736578000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":25,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032375","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}